Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is exclusively focused on capital structure and voting rights.
- Issued Share Capital (as of July 29, 2011): 5,604,870,917 Ordinary shares of 25p each.
- Treasury Shares: 494,796,816 Ordinary shares.
- Total Voting Rights: 5,110,074,101.
Material Changes
The filing text does not provide a clear value for material changes versus the prior comparable period regarding financial performance or operational metrics. The document only states the current share capital composition as of July 29, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains no forward-looking statements or risk disclosures.
Important Facts for Investors to Verify
- Verify the total number of voting rights (5,110,074,101) to determine if disclosure thresholds under the Financial Services Authority's Disclosure and Transparency Rules have been met.
- Confirm the number of shares held in Treasury (494,796,816) when calculating the denominator for ownership interest notifications.
- Note that this filing does not contain financial performance data; investors should refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.